产品名称
硫唑嘌呤, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
SMILES string
Cn1cnc(c1Sc2ncnc3[nH]cnc23)[N+]([O-])=O
InChI key
LMEKQMALGUDUQG-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
azathioprine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... PPAT(5471)
正在寻找类似产品? 访问 产品对比指南
Application
Azathioprine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Fernando Magro et al.
The American journal of gastroenterology, 109(7), 1026-1036 (2014-05-07)
Crohn's disease (CD) induces cumulative structural damage, initially characterized by a non-stenosing non-penetrating behavior (B1) with progression over time to a fibro-stenosing (B2) and/or penetrating phenotype (B3). Our aim was to assess the long-term evolution of disease behavior of CD
Loïc Guillevin et al.
The New England journal of medicine, 371(19), 1771-1780 (2014-11-06)
The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission.
Manuel Rodríguez-Perálvarez et al.
Current opinion in organ transplantation, 19(3), 253-260 (2014-04-02)
Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression. There is accumulating evidence linking increased exposure to immunosuppressants and carcinogenesis, particularly concerning calcineurin
D Dooremont et al.
Acta gastro-enterologica Belgica, 76(3), 342-346 (2013-11-23)
We report 3 male IBD patients (2 Crohn's Disease, 1 Ulcerative Colitis) developing thrombocytopenia and splenomegaly on azathioprine treatment. All patients were diagnosed with significant portal hypertension due to histological proven nodular regenerative hyperplasia (NRH) of the liver. In two
Helen French et al.
Digestive diseases and sciences, 56(7), 1929-1936 (2011-04-09)
The duration of use of azathioprine (Aza) and 6-mercaptopurine (6-MP) for maintaining remission for Crohn's disease is debatable. To examine whether Aza/6-MP can be safely withdrawn in patients with Crohn's disease who have been in remission. The following databases were
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持